Acceleron Pharma raises $30 million through private financing Acceleron Pharma, Inc., a biopharmaceutical company developing proteins therapeutics for tumor and orphan illnesses, today announced it elevated a $30M private financing. Celgene, among Acceleron’s strategic partners, and all the existing investors participated in this financing. The proceeds will be utilized to expand and advance Acceleron’s clinical stage pipeline also to continue steadily to support its highly productive study engine.D., Chief Executive Officer of Acceleron.Neither of these parties endorse or recommend any commercial products, services, or equipment.. Affordable Care Act can help strengthen trauma systems Traumatic injuries will be the leading cause of death and disability for people beneath the age of 45 and the fourth-leading cause of death for people of most ages. Much progress has been made during the last 50 years in developing statewide regionalized trauma systems to look after these injuries, in the December issue of Health Affairs but authors of a review appearing, believe more function is needed to ensure the right patient gets to the right place at the proper time, and that the Affordable Care Action may offer possibilities to improve trauma systems.